Angiotensin II type I receptor and miR-155 in endometrial cancers: Synergistic antiproliferative effects of anti-miR-155 and losartan on endometrial cancer cells

Gynecologic Oncology

Volumn 126, Issue 1, 2012, Pages 124-131

  Choi, Chel Hun ^a   Park, Young Ae ^a   Choi, Jung Joo ^a   Song, Taejong ^b   Song, Sang Yong ^a   Lee, Yoo Young ^a   Lee, Jeong Won ^a   Kim, Tae Joong ^a   Kim, Byoung Gie ^a   Bae, Duk Soo ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b CHA University   (South Korea)

Author keywords

AGTR1; Endometrial carcinoma; Losartan; MicroRNA; miR 155

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; AMBION; ANGIOTENSIN 1 RECEPTOR; ANTINEOPLASTIC AGENT; LOSARTAN; MICRORNA 155; UNCLASSIFIED DRUG;

ADULT; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CANCER SURVIVAL; CANCER TISSUE; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MULTIVARIATE ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; COMBINED MODALITY THERAPY; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LOSARTAN; MICRORNAS; MIDDLE AGED; OLIGONUCLEOTIDES, ANTISENSE; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ANGIOTENSIN; SEQUENCE ANALYSIS, DNA; TRANSFECTION;

EID: 84862773362     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.04.020     Document Type: Article

References (28)

1. Persson I, Adami HO, Bergkvist L, Lindgren A, Pettersson B, Hoover R, et al. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. BMJ 1989;298:147-51. (Pubitemid 19039672)
2. Soler M, Chatenoud L, Negri E, Parazzini F, Franceschi S, la Vecchia C. Hypertension and hormone-related neoplasms in women. Hypertension 1999;34:320-5. (Pubitemid 29409235)
3. Lucenteforte E, Bosetti C, Talamini R, Montella M, Zucchetto A, Pelucchi C, et al. Diabetes and endometrial cancer: effect modification by body weight, physical activity and hypertension. Br J Cancer 2007;97:995-8. (Pubitemid 47519295)
4. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008;371:569-78. (Pubitemid 351232031)
5. Burbos N, Musonda P, Giarenis I, Shiner AM, Giamougiannis P, Morris EP, et al. Predicting the risk of endometrial cancer in postmenopausal women presenting with vaginal bleeding: the Norwich DEFAB risk assessment tool. Br J Cancer 2010;102:1201-6.
6. Leung PS. The physiology of a local renin-angiotensin system in the pancreas. J Physiol 2007;580:31-7. (Pubitemid 46470642)
7. Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA 1995;273:1605-9.
8. Deshayes F, Nahmias C. Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab 2005;16:293-9. (Pubitemid 41206635)
9. Leung PS, Suen PM, Ip SP, Yip CK, Chen G, Lai PB. Expression and localization of AT1 receptors in hepatic Kupffer cells: its potential role in regulating a fibrogenic response. Regul Pept 2003;116:61-9. (Pubitemid 37352916)
10. Pupilli C, Lasagni L, Romagnani P, Bellini F, Mannelli M, Misciglia N, et al. Angiotensin II stimulates the synthesis and secretion of vascular permeability factor/vascular endothelial growth factor in human mesangial cells. J Am Soc Nephrol 1999;10:245-55. (Pubitemid 29068063)
11. Ager EI, Neo J, Christophi C. The renin-angiotensin system and malignancy. Carcinogenesis 2008;29:1675-84.
12. Lee JW, Park YA, Choi JJ, Lee YY, Kim CJ, Choi C, et al. The expression of the miRNA-200 family in endometrial endometrioid carcinoma. Gynecol Oncol 2011;120: 56-62.
13. Nikiforova MN, Tseng GC, Steward D, Diorio D, Nikiforov YE. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab 2008;93:1600-8. (Pubitemid 351656494)
14. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006;103:2257-61. (Pubitemid 43271657)
15. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005;65: 7065-70. (Pubitemid 41161233)
16. Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL, et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 2008;14:2348-60.
17. Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner MR, Frankel WL, et al. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer 2007;120:1046-54. (Pubitemid 46214304)
18. Szafranska AE, Davison TS, John J, Cannon T, Sipos B, Maghnouj A, et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 2007;26:4442-52. (Pubitemid 47014466)
19. Martin MM, Lee EJ, Buckenberger JA, Schmittgen TD, Elton TS. MicroRNA-155 regulates human angiotensin II type 1 receptor expression in fibroblasts. J Biol Chem 2006;281:18277-84. (Pubitemid 44035484)
20. Lee JW, Choi CH, Choi JJ, Park YA, Kim SJ, Hwang SY, et al. Altered microRNA expression in cervical carcinomas. Clin Cancer Res 2008;14:2535-42.
21. Choi CH, Lee JS, KimSR, Lee YY, KimCJ, Lee JW, et al. Direct inhibition of eIF4E reduced cell growth in endometrial adenocarcinoma. J Cancer Res Clin Oncol 2011;137:463-9.
22. Takeda H, Kondo S. Differences between squamous cell carcinoma and keratoacanthoma in angiotensin type-1 receptor expression. Am J Pathol 2001;158: 1633-7. (Pubitemid 32422928)
23. De Paepe B, Verstraeten VL, De Potter CR, Vakaet LA, Bullock GR. Growth stimulatory angiotensin II type-1 receptor is upregulated in breast hyperplasia and in situ carcinoma but not in invasive carcinoma. Histochem Cell Biol 2001;116: 247-54. (Pubitemid 32930137)
24. Levine RL, Cargile CB, Blazes MS, van Rees B, Kurman RJ, Ellenson LH. PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma. Cancer Res 1998;58: 3254-8. (Pubitemid 28371061)
25. Emons G, Fleckenstein G, Hinney B, Huschmand A, Heyl W. Hormonal interactions in endometrial cancer. Endocr Relat Cancer 2000;7:227-42. (Pubitemid 32175106)
26. Vinson GP, Ho MM, Puddefoot JR. The distribution of angiotensin II type 1 receptors, and the tissue renin-angiotensin systems. Mol Med Today 1995;1:35-9.
27. Piastowska-Ciesielska AW, Pluciennik E, Wojcik-Krowiranda K, Bienkiewicz A, Bednarek A, Ochedalski T. Analysis of the expression of angiotensin II type 1 receptor and VEGF in endometrial adenocarcinoma with different clinicopathological characteristics. Tumour Biol 2011 [Electronic publication ahead of print].
28. van Rooij E, Olson EN. MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets. J Clin Invest 2007;117:2369-76. (Pubitemid 47494334)